Skip to content
Screener

Other geography segments

Europe, the Middle East and Africa
$10.45M+24.5%
Asia Pacific
$9.32M+14.2%
Latin and Central America
$386K+88.3%

Similar metrics at other companies

Coherent logo
COHRNorth America — Revenue
$1.16B+23.3%
Planet Labs logo
PLNorth America — Revenue
$37.04M+25.4%
Ubiquiti Inc. logo
UINorth America — Revenue
$410.21M+27.1%
AMB
AMBQNorth America — Revenue
$5.13M+20,416%
AMC Robotics Corporation logo
AMCINorth America — Revenue
$1.18M-2.5%
CVD Equipment Corp. logo
CVVNorth America — Revenue
$1K-66.7%

Other financials

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
Operating cash flow$4.0M+139%
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation

See full
Market cap$918.96M+210%
Enterprise value$1.03B+158%
P/S4.4×+3.1×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001823239-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$51,442$47,397$117,279$94,247
Cost of revenue30,79239,62962,92878,754
Gross profit20,6507,76854,35115,493
Operating expenses:
Selling, general and administrative32,07038,71561,16278,279
Research and development3,7024,8827,5919,770
Goodwill impairment30,44942,884
Restructuring(33)2,845

Item 1. Financial Statements

FAQ

What is Maravai LifeSciences Holdings, Inc.'s north america — revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported north america — revenue of $31.28M in Q2 2026.
How has Maravai LifeSciences Holdings, Inc.'s north america — revenue changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s north america — revenue increased by 2.1% year-over-year, from $30.64M to $31.28M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s north america — revenue?
Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s north america — revenue has grown at a -22.8% compound annual growth rate (CAGR), from $317.07M to $112.38M.
What does north america — revenue mean?
This metric represents the total gross sales generated from products and services provided to customers located within the North American geographic region. It serves as a key indicator of regional market demand for nucleic acid production and biologics safety testing solutions. Tracking this figure helps investors assess the company's geographic footprint and its ability to capture market share in a critical life sciences hub.

Ask your AI about Maravai LifeSciences Holdings, Inc.'s north america — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude